

TABLE OF CONTENTS

May 17, 2010

No. 2188

BUSINESS

- 1 BI Expects 1st Approval for Dabigatran for SPAF in Late 2010
 - SSP to Enhance BI's OTC Drugs Development Capability
 - Production Site for Dabigatran to Be Expanded: BI
 - Sales Increased 9.7% in 2009 Driven by Spiriva
 - Sales Increases for 3 Mainstay Products in Japan
- 3 Chugai to Educate Top Oncology MRs
- 3 Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
- 4 Janssen: Sales Up 2.7% to ¥80.5 Bil.
- 4 Torii to Boost Sales to ¥50 Bil. by FY2012
 - Sales Driven by Remitch Capsule
- 5 METI Presents Report on Pharma Industry Promotion
- 6 How Will Distribution Practice Be Improved Following Pricing System Reform?
- 10 **BUSINESS NEWS IN BRIEF**
 - Santen Licenses ATL313 from Clinical Data
 - Kissei Licenses Proaerolysin from Prottox
 - Takeda Settles Actos Patent Infringement Litigations in US

REGULATORY

- 11 *Koroshō's* Growth Strategy Calls For Development of New Drugs, Medical Devices
- 11 *Koroshō*, METI Set Up Joint Task Force to Promote New Growth Strategy
- 12 PMDA Should Continue, Even Expand Its Activities: Screening by GRU
 - Criticism Centers on Large Number of Executives from *Koroshō*
 - PMDA Will Accept Only Young Officials from *Koroshō*: Dr Kondo
- 13 PMDA to Relax Working Regulations for Former Company Employees
- 14 Five NIBIO Projects Screened by GRU
 - Integration of NIBIO with NIHN Will Generate Synergism: Dr Yamanishi
- 15 *Koroshō* to Ask for Development of 109 Drugs/Indications
 - Some Indications May Be Approved by Modifying Package Inserts
- 16 WG to Discuss Regulatory Requirements for Regenerative Medicine
- 16 GRU to Call For Lifting on Ban on Supply of Inf. on Unapproved Drugs

17 REGULATORY NEWS IN BRIEF

- Takeda Applies for Successor of Blopress in the US
- Eisai Applies for Reflux Esophagitis for Pariet
- Abbott Japan Applies for Kaletra for Once Daily Treatment
- DSP's Eslicarbazepine Not Approved by FDA
- 2 Chemo Regimens Approved as Advanced Healthcare Services
- Peptide Vaccine Therapy for Bladder Cancer Recommended for Conditional Approval
- Package Inserts for DPP-4 Inhibitors, GLP-1 Analogue to Be Modified
- Reimbursement Method to Be Reviewed for 23 Products

R&D

- 20 LDP, JPMA Exchange Opinions on How to Promote Clinical Trials in Japan
- 20 **R&D NEWS IN BRIEF**
 - Collategene Achieves Primary Endpoint in PIII Trial: AnGes MG
 - Asahi Kasei's AT-877 Fails to Meet Primary Endpoint in PIII
 - Hisamitsu's HKT-500 Fails to Meet Primary Endpoint in PIII
 - NIBIO Identifies Protein Related to Colon, Esophageal Cancer
 - Lixisenatide Significantly Reduces HbA1c: sanofi-aventis

MEDICAL FACILITIES & NURSING CARE

- 21 Merck Serono Begins Infertility Treatment Education Program
- 22 New JMA Leadership to Follow Former Leadership's Policies
 - Dr Suzuki to Represent JMA at *Chuikyo*
- 22 Good Control of Nocturnal Respiratory Symptoms Important in Children: Prof. Mochizuki
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Treatment Cost Holds Key in Selection of ARB/CCB Combinations: Dr Ogihara
 - 68% of Public "Don't Know About HPV": Survey